Skip to main content

Table 3 Perceived facilitators and barriers to acceptance and completion of 3HP expressed in terms of their Behavioral determinants within the COM-B model

From: Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives

Behavioral Determinants 

Emergent themes

PLHIV

Health workers

Facilitators

Capability (psychological)

• Aware of being potentially at risk of TB

• Awareness of easy transmission of TB

• Knowledge that TB causes the highest mortality among PLHIV at the clinic

Opportunity (physical)

 

• Streamlined clinic visits

Motivation (reflective)

• Willingness to take TPT

• Trust in health workers

• Perceived benefits of DOT/SAT

• PLHIV trust health workers

• PLHIV are receptive to TPT

• Convenience of once-weekly 3HP dosing schedule

• Perceived benefits of DOT/SAT

Motivation (automatic)

• Fear of contracting TB

• PLHIV fear TB

Barriers

Capability (physical)

• Potential pill burden (difficulty to swallow many pills)

• Technology challenges

• Potential pill burden (difficulty to swallow many pills)

Capability (psychological)

• Inadequate understanding of TPT

• Inadequate understanding of TB and TPT

Opportunity (social)

 

• Stigma associated with TB

Motivation (reflective)

• Perceived challenges of DOT/SAT

• Concerns about the effectiveness of 3HP

• Perceived challenges of DOT/SAT

Motivation (automatic)

• Fear of potential side effects

• PLHIV’s fear of potential side effects

  1. Abbreviations: 3HP rifapentine-Isoniazid combination, COM-B capability opportunity motivation behavior model, TB tuberculosis, PLHIV person/people living with HIV, TPT tuberculosis preventive therapy, DOT directly observed therapy, SAT self-administered therapy